|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arbyn M, Castellsagué X, de Sanjosé S,
Bruni L, Saraiya M, Bray F and Ferlay J: Worldwide burden of
cervical cancer in 2008. Ann Oncol. 22:2675–2686. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lăără E, Day NE and Hakama M: Trends in
mortality from cervical cancer in the Nordic countries: Association
with organised screening programmes. Lancet. 1:1247–1249. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hakama M and Louhivuori K: A screening
programme for cervical cancer that worked. Cancer Surv. 7:403–416.
1988.PubMed/NCBI
|
|
5
|
Bodily J and Laimins LA: Persistence of
human papillomavirus infection: Keys to malignant progression.
Trends Microbiol. 19:33–39. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Münger K, Werness BA, Dyson N, Phelps WC,
Harlow E and Howley PM: Complex formation of human papillomavirus
E7 proteins with the retinoblastoma tumor suppressor gene product.
EMBO J. 8:4099–4105. 1989.PubMed/NCBI
|
|
7
|
Scheffner M, Werness BA, Huibregtse JM,
Levine AJ and Howley PM: The E6 oncoprotein encoded by human
papillomavirus types 16 and 18 promotes the degradation of p53.
Cell. 63:1129–1136. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Crook T, Tidy JA and Vousden KH:
Degradation of p53 can be targeted by HPV E6 sequences distinct
from those required for p53 binding and trans-activation. Cell.
67:547–556. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boyer SN, Wazer DE and Band V: E7 protein
of human papilloma virus-16 induces degradation of retinoblastoma
protein through the ubiquitin-proteasome pathway. Cancer Res.
56:4620–4624. 1996.PubMed/NCBI
|
|
10
|
DiSaia PJ and Creasman WT: Cervical
CancerClinical Gynecologic Oncology. 5th. Mosby; Maryland Heights:
pp. 1–106. 1997
|
|
11
|
Deeks SG, Smith M, Holodniy M and Kahn JO:
HIV-1 protease inhibitors. A review for clinicians. JAMA.
277:145–153. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sgadari C, Barillari G, Toschi E, Carlei
D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R,
Malavasi L, et al: HIV protease inhibitors are potent
anti-angiogenic molecules and promote regression of Kaposi sarcoma.
Nat Med. 8:225–232. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Monini P, Sgadari C, Toschi E, Barillari G
and Ensoli B: Antitumour effects of antiretroviral therapy. Nat Rev
Cancer. 4:861–875. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Russo SM, Tepper JE, Baldwin AS Jr, Liu R,
Adams J, Elliott P and Cusack JC Jr: Enhancement of
radiosensitivity by proteasome inhibition: Implications for a role
of NF-kappaB. Int J Radiat Oncol Biol Phys. 50:183–193. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pajonk F, Himmelsbach J, Riess K, Sommer A
and McBride WH: The human immunodeficiency virus (HIV)-1 protease
inhibitor saquinavir inhibits proteasome function and causes
apoptosis and radiosensitization in non-HIV-associated human cancer
cells. Cancer Res. 62:5230–5235. 2002.PubMed/NCBI
|
|
16
|
Gaedicke S, Firat-Geier E, Constantiniu O,
Lucchiari-Hartz M, Freudenberg M, Galanos C and Niedermann G:
Antitumor effect of the human immunodeficiency virus protease
inhibitor ritonavir: Induction of tumor-cell apoptosis associated
with perturbation of proteasomal proteolysis. Cancer Res.
62:6901–6908. 2002.PubMed/NCBI
|
|
17
|
Pati S, Pelser CB, Dufraine J, Bryant JL,
Reitz MS Jr and Weichold FF: Antitumorigenic effects of HIV
protease inhibitor ritonavir: Inhibition of Kaposi sarcoma. Blood.
99:3771–3779. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
André P, Groettrup M, Klenerman P, de
Giuli R, Booth BL Jr, Cerundolo V, Bonneville M, Jotereau F,
Zinkernagel RM and Lotteau V: An inhibitor of HIV-1 protease
modulates proteasome activity, antigen presentation, and T cell
responses. Proc Natl Acad Sci USA. 95:13120–13124. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schmidtke G, Holzhütter HG, Bogyo M,
Kairies N, Groll M, de Giuli R, Emch S and Groettrup M: How an
inhibitor of the HIV–I protease modulates proteasome activity. J
Biol Chem. 274:35734–35740. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Piccinini M, Rinaudo MT, Chiapello N,
Ricotti E, Baldovino S, Mostert M and Tovo PA: The human 26S
proteasome is a target of antiretroviral agents. AIDS. 16:693–700.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goldberg AL and Rock K: Not just research
tools-proteasome inhibitors offer therapeutic promise. Nat Med.
8:338–340. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barillari G, Iovane A, Bacigalupo I,
Palladino C, Bellino S, Leone P, Monini P and Ensoli B: Ritonavir
or saquinavir impairs the invasion of cervical intraepithelial
neoplasia cells via a reduction of MMP expression and activity.
AIDS. 26:909–919. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hampson L, Kitchener HC and Hampson IN:
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to
degrade p53 and selectively kill E6-dependent cervical carcinoma
cells in vitro. Antivir Ther. 11:813–825. 2006.PubMed/NCBI
|
|
24
|
Justesen US: Protease inhibitor plasma
concentrations in HIV antiretroviral therapy. Dan Med Bull.
55:165–185. 2008.PubMed/NCBI
|
|
25
|
Monini P, Sgadari C, Grosso MG, Bellino S,
Di Biagio A, Toschi E, Bacigalupo I, Sabbatucci M, Cencioni G,
Salvi E, et al: Clinical course of classic Kaposi's sarcoma in
HIV-negative patients treated with the HIV protease inhibitor
indinavir. AIDS. 23:534–538. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Flick DA and Gifford GE: Comparison of in
vitro cell cytotoxic assays for tumor necrosis factor. J Immunol
Methods. 68:167–175. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tanaka K, Mizushima T and Saeki Y: The
proteasome: Molecular machinery and pathophysiological roles. Biol
Chem. 393:217–234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bertuzzi A, Gandolfi A, Germani A, Spanò
M, Starace G and Vitelli R: Analysis of DNA synthesis rate of
cultured cells from flow cytometric data. Cytometry. 5:619–628.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kalantari M, Karlsen F, Kristensen G, Holm
R, Hagmar B and Johansson B: Disruption of the E1 and E2 reading
frames of HPV 16 in cervical carcinoma is associated with poor
prognosis. Int J Gynecol Pathol. 17:146–153. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J and Westin SN: Rational selection of
biomarker driven therapies for gynecologic cancers: The more we
know, the more we know we don't know. Gynecol Oncol. 141:65–71.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee CG, Gottesman MM, Cardarelli CO,
Ramachandra M, Jeang KT, Ambudkar SV, Pastan I and Dey S: HIV-1
protease inhibitors are substrates for the MDR1 multidrug
transporter. Biochemistry. 37:3594–3601. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kraus M, Bader J, Overkleeft H and
Driessen C: Nelfinavir augments proteasome inhibition by bortezomib
in myeloma cells and overcomes bortezomib and carfilzomib
resistance. Blood Cancer J. 3:e1032013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kraus M, Malenke E, Gogel J, Müller H,
Rückrich T, Overkleeft H, Ovaa H, Koscielniak E, Hartmann JT and
Driessen C: Ritonavir induces endoplasmic reticulum stress and
sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol
Cancer Ther. 7:1940–1948. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Taura M, Kariya R, Kudo E, Goto H, Iwawaki
T, Amano M, Suico MA, Kai H, Mitsuya H and Okada S: Comparative
analysis of ER stress response into HIV protease inhibitors:
Lopinavir but not darunavir induces potent ER stress response via
ROS/JNK pathway. Free Radic Biol Med. 65:778–788. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gupta AK, Cerniglia GJ, Mick R, McKenna WG
and Muschel RJ: HIV protease inhibitors block Akt signaling and
radiosensitize tumor cells both in vitro and in vivo. Cancer Res.
65:8256–8265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ikezoe T, Saito T, Bandobashi K, Yang Y,
Koeffler HP and Taguchi H: HIV-1 protease inhibitor induces growth
arrest and apoptosis of human multiple myeloma cells via
inactivation of signal transducer and activator of transcription 3
and extracellular signal-regulated kinase 1/2. Mol Cancer Ther.
3:473–479. 2004.PubMed/NCBI
|
|
37
|
Laurent N, de Boüard S, Guillamo JS,
Christov C, Zini R, Jouault H, Andre P, Lotteau V and Peschanski M:
Effects of the proteasome inhibitor ritonavir on glioma growth in
vitro and in vivo. Mol Cancer Ther. 3:129–136. 2004.PubMed/NCBI
|
|
38
|
Berkers CR, Verdoes M, Lichtman E,
Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H and Galardy
PJ: Activity probe for in vivo profiling of the specificity of
proteasome inhibitor bortezomib. Nat Methods. 2:357–362. 2005.
View Article : Google Scholar : PubMed/NCBI
|
